For example, Bevacizumab and cetuximab has been reported to target FCGR1A and FCGR2B (Imming et al., 2006; Bogdanovich et al., 2016), and these 2 drugs (Moore et al., 2012; Zighelboim et al., 2013; Tewari et al., 2014; Penson et al., 2015) have already been approved for clinical treatment of cervical cancer. The gene discussed is FCGR2B; the disease is cervical carcinoma.